Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.37
-0.8700-6.57%
Pre-market: 12.440.0683+0.55%06:24 EDT
Volume:3.74M
Turnover:46.94M
Market Cap:1.46B
PE:-3.25
High:13.16
Open:13.12
Low:12.12
Close:13.24
52wk High:28.25
52wk Low:5.90
Shares:118.13M
Float Shares:112.00M
Volume Ratio:0.91
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8100
EPS(LYR):-3.8100
ROE:-53.48%
ROA:-27.11%
PB:2.18
PE(LYR):-3.25

Loading ...

Stock Track | Intellia Therapeutics Soars 5.01% Intraday After FDA Lifts Clinical Hold on Heart Disease Gene Therapy Trial

Stock Track
·
Mar 02

Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), Eton Pharmaceuticals (ETON) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 02

Stock Track | Intellia Therapeutics Plummets 5.07% Intraday as ATM Offering Expansion Offsets FDA Clinical Hold Lift

Stock Track
·
Mar 02

BUZZ-U.S. STOCKS ON THE MOVE -Duolingo, AES, NextDecade

Reuters
·
Mar 02

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)

TIPRANKS
·
Mar 02

BRIEF-Intellia Therapeutics Inc - Increases At-The-Market Offering Program To $1.04 Billion- SEC Filing

Reuters
·
Mar 02

Intellia Therapeutics Inc - Increases at-the-Market Offering Program to $1.04 Bln- SEC Filing

THOMSON REUTERS
·
Mar 02

Intellia Shares Jump Premarket After FDA Removes Hold on Clinical Trial

Dow Jones
·
Mar 02

Intellia Therapeutics Shares Gain 7% Premarket After US FDA Lifts Clinical Hold on Co's Heart Disease Gene Therapy Trial

THOMSON REUTERS
·
Mar 02

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Reuters
·
Mar 02

Stock Track | Intellia Therapeutics Soars 6.24% in Pre-market on Analyst Bullish Call

Stock Track
·
Mar 02

Intellia Says FDA Lifts Clinical Hold on MAGNITUDE Phase 3 ATTR-CM Trial

Reuters
·
Mar 02

Intellia Therapeutics Announces FDA Lift of Clinical Hold on Magnitude Phase 3 Clinical Trial in Attr-Cm

THOMSON REUTERS
·
Mar 02

H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 02

Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone

TIPRANKS
·
Feb 28

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Feb 27

Wedbush Raises Price Target on Intellia Therapeutics to $12 From $7, Keeps Neutral Rating

MT Newswires Live
·
Feb 27

Stock Track | Intellia Therapeutics Plunges 5.46% After-Hours Despite Earnings Beat on Cash Burn and Clinical Hold Concerns

Stock Track
·
Feb 27

Stock Track | Intellia Therapeutics Soars 5.07% Intraday on Strong Q4 Earnings Beat and Positive Pipeline Updates

Stock Track
·
Feb 27

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)

TIPRANKS
·
Feb 27